Inhibition of NF-κB activation sensitizes U937 cells to 3′-azido-3′-deoxythymidine induced apoptosis by Matteucci, C et al.









4,5 and A Mastino*
,2,3
In this study, we investigated molecular mechanisms underlying low susceptibility to apoptosis induced by the nucleoside
analog azidothymidine (AZT) and the role of nuclear factor-jB (NF-jB) activation in these phenomena. A preliminary screening
in different cell lines indicated U937 monocytic cell line as suitable to this purpose. Treatment of U937 cells even with
suprapharmacological concentrations of AZT induced only moderate levels of apoptosis. Surprisingly, SuperArray analysis
showed that AZT induced the transcriptional activity of both pro- and anti-apoptotic genes. Interestingly, moreover, several
genes upregulated by AZT were NF-jB related. In fact, AZT, after an initial inhibition of NF-jB activation with respect to control,
induced a transient, but consistent, increase in NF-jB-binding activity. Inhibition of NF-jB activation in U937 cells, stably
transfected with a dominant-negative IjBa or by pharmacological treatment, sensitized them to apoptosis induced by AZT and
impaired the upregulation of anti-apoptotic genes in response to AZT treatment, with respect to control cells. These results
indicatethatNF-jBactivationbyAZThasaroleinprotectingtargetcellsfromapoptoticcelldeath,improvingourunderstanding
of the toxicology and the therapeutic usage of this drug.
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Azidothymidine (30-azido-30-deoxythymidine, AZT) was the
ﬁrst anti-HIV compound introduced in clinics in 1987.
1 This
drug is considered the prototype of a class of anti-retrovirals
(ARV), sharing the common nucleoside/nucleotide structure
and the mechanism of action.
2 After its failure as an anti-HIV
monotherapeutic agent, AZT became one of the pillars of
the combination therapy strategy with three or more ARV
in HIV-infected adults and for preventing HIV infection in
infants by antepartum, intrapartum and postpartum regimens.
Particularly, lower cost connected with patent expiration
in 2004 and availability of ﬁxed-dose formulations in which
AZT is combined with other ARV, greatly favors AZT usage in
resource-limited countries, where access to ARV therapy
exponentially grew in the recent years.
3
Although beneﬁts associated with AZT-based anti-HIV
treatment are unequivocal, a series of severe adverse reac-
tions, including bone marrow suppression, were observed
in patients after prolonged assumption of the drug since
the beginning of the era of ARV therapy.
4 In particular, more
recent studies identiﬁed cytotoxic, genotoxic and terato-
genetic potentials of AZT as a main possible cause of
undesirable pathological consequences in adults and
infants.
5–8 Regarding cytotoxicity, AZT was shown to cause
cell cycle arrest in S phase by directly targeting cell poly-
merases or proteins involved in cell cycle regulation.
9–11
Checkpoint-arrested cells are known to switch on repair
mechanisms,
12 which potentially generate mutations. This
could link the cytotoxic with the mutagenic activity of AZT.
13
Alternatively, DNA damage could trigger apoptosis.
14 In fact,
AZT has been reported to induce apoptosis
15 and this form
of programmed cell death has been hypothesized to have
a role in AZT-induced pathologies.
16 However, no conclusive
evidence exists supporting a noticeable pro-apoptotic activity
of AZT and molecular mechanisms involved. In particular, our
recent results highlighted that acute treatment of peripheral
blood mononuclear cells with AZT in vitro induced a
remarkable expression/activation of caspases, although in
the absence of a reliable induction of apoptosis.
17 Our
hypothesis was that the apparent resistance to cell death
was owed to a sort of ‘precommitment’ to apoptosis by AZT,
lacking sufﬁcient downstream apoptotic signals. In fact, the
lack of ﬁnal commitment to apoptosis could explain the geno-
toxic/teratogenetic/ pro-carcinogenic effects of AZT.
5–7,18
One of the main systems involved in the resistance to
chemotherapy-induced apoptosis is the nuclear factor-kB
(NF-kB) signaling pathway.
19,20 The NF-kB system has a key
role as regulator of inﬂammations, cell proliferation and
of early pathogen response.
21,22 Transcriptional regulation
of NF-kB generally promotes survival and protects cells
from apoptosis by inducing expression of genes encoding
anti-apoptoticproteins.
23,24However,NF-kBhasbeenshown
to be endowed with a contradictory role in cell death and
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25,26 controlling the expression of both pro-
apoptotic and anti-apoptotic genes.
27,28
In this context, the primary aim of this study was to
investigatemolecularmechanismsunderlyingsusceptibilityto
AZT-inducedapoptosistoameliorateourunderstandingofthe
toxicology and the therapeutic usage of this drug. Surpris-
ingly, we found, using monocytic U937 cells as an experi-
mental model, that AZT activated the transcription of both
pro-apoptotic and anti-apoptotic genes belonging to the
NF-kB-dependent pathway. Moreover, results demonstrated
that inhibition of NF-kB activation signiﬁcantly enhanced the
apoptotic response to AZT in U937 cells.
Results
AZT induces apoptotic cell death in U937 cells only at
suprapharmacological concentrations. A preliminary
screening in different cell lines of lymphocytic/monocytic
origin showed that most of the cells were quite resistant
to AZT-induced apoptosis, even when challenged at supra-
pharmacological concentrations of the drug. Among the
others, however, U937 monocytic cells showed the best
dose- and time-dependent response to apoptosis induction
when exposed to AZT in vitro. Figure 1a shows the time
course of the dose-effect study. Susceptibility to apoptosis
was measured in U937 cells treated with vehicle, 8, 32 and
128mM AZT at different times by ﬂow cytometry analysis of
hypodiploid events referring to propidium iodide (PI)-stained
nuclei. The in vitro concentration of 8mM AZT approximately
corresponds to the pharmacological level utilized in ARV
therapy in vivo, although higher concentrations of the
drug were used as suprapharmacological concentrations.
The results are the mean values±S.E. obtained from
three independent experiments. No signiﬁcant increase in
apoptosis was observed after 3 and 6h in culture, whereas
after 18h of treatment with AZT, U937 cells showed
signiﬁcantly increased levels of apoptosis in comparison
with control samples only at 32mM AZT and 128mM
(P¼0.042 and P¼0.034, respectively). A more signiﬁcant
increase in hypodiploid events in comparison with control
samples occurred at 24h (CTR versus 32mM AZT,
P¼0.033; CTR versus 128mM AZT, Po0.001) and 48h
(32mM AZT and 128mM AZT versus CTR, Po0.001) after
AZT addition. However, even in the best pro-apoptotic
conditions found (128mM AZT, 48h), only a minority of the
cells (o45%) underwent apoptosis. To conﬁrm the results
with another method of apoptosis detection and to further
characterize the features of cell death induced by AZT, the
percentage of annexin-Vþ and PIþ U937 cells, treated
with the highest suprapharmacological concentration of AZT,
was evaluated by two-ﬂuorescence ﬂow cytometry analysis
(Figure 1b). After 18h of treatment, results showed 5%
annexin-VþPIþ (late apoptotic/necrotic) cells and 39%
annexin-Vþ/PI  (early apoptotic) cells, whereas the
control sample showed 2% annexin-VþPIþ cells and 5%
annexin-Vþ/PI  cells, respectively. After 48h of treatment
with AZT, evaluation of apoptosis in the same experiment
by means of hypodiploid nuclei counting showed 42% of
positive events versus 12% of positive events in the control
sample (Figure 1c). Thus, percentage of early apoptotic
cells at 18h, using the annexin-V/PI method (Figure 1b), was
very similar to percentage hypodiploid apoptotic events
observed later on at 48h in the same sample (Figure 1c).
These data indicate that cell death induced in U937 cells
by AZT occurred mainly, if not exclusively, by apoptosis.
On the basis of these results, U937 cells were selected
as a suitable experimental model to further investigate
mechanisms involved in AZT-induced sensitivity/resistance
to apoptotic cell death.
Figure 1 Effect of AZT on apoptosis in U937 cell. (a) U937 cells were treated with 0, 8, 32, 128mM AZT for 3, 6, 18, 24 and 48h and apoptosis was evaluated by
hypodiploid nuclei analysis after DNA staining with PI. Apoptosis was evaluated by ﬂow cytometry analysis of hypodiploid nuclei and expressed as mean values ± S.E.
obtained from three independent experiments; asterisk indicates a signiﬁcant difference versus CTR (*Po0.05; **Po0.010). (b) FACS analysis of annexin-V and PI in U937
cells treated with vehicle or 128mM AZT, after 18h in culture. (c) Percentage of hypodiploid nuclei in U937 cells treated with vehicle or 128mM AZT, after 48h in culture.
In Figure 1b and c one representative out of the three independent experiments performed is shown
NF-jB and AZT-induced apoptosis
C Matteucci et al
2
Cell Death and DiseaseAZT modulates NF-jB activation in U937 cells. To
investigate mechanisms underlying scarce sensitivity to
AZT-induced apoptosis, we investigated transcriptional
levels of hundred genes in response to AZT treatment in
U937 cells through SuperArray analysis following exposure
to 128mM AZT for 18h. In addition to apoptosis-related
genes, also the transcriptional levels of genes involved in
the cell cycle and DNA-repair pathways were evaluated.
The results, shown as Supplementary materials (Supple-
mentary Table S1), indicated a number of genes for which
transcriptional levels were considered as signiﬁcantly
modiﬁed. As expected, mRNA levels for some caspase
genes and other genes that can be classiﬁed as pro-
apoptotic were found to be upregulated. Surprisingly,
however, SuperArray analysis showed that AZT induced
also the transcriptional activity of some anti-apoptotic genes.
Interestingly, several genes whose expression was shown to
be modulated by AZT were found to be involved in the NF-kB
pathway. However, AZT was reported to presumably inhibit
NF-kB activation.
29,30 We, then, veriﬁed the capability of
AZT to directly affect the activation of the NF-kB complex in
our experimental conditions. For this purpose, ﬁrst U937 cells
were either exposed to vehicle or treated with 128mM AZT
and, at different times after treatment, NF-kB activation was
assayed in nuclear lysates from experimental samples by
revealing the DNA-binding activity using non-radioactive
electromobility shift assay (EMSA). As shown in Figure 2a,
comparison of the bands visualized from control and treated
samples at corresponding times of incubation indicated, in
agreement with results from other authors, the inhibition of
NF-kB-binding activity early after exposure to the drug and
in the late time, that is, at 0.5 and 24h after treatment.
However, unexpectedly, a noticeable rise of the NF-kB
complex-binding activity consistently occurred at 6h of
treatment. Addition of the unlabeled kB DNA probe to the
6h sample completely abolished the band visualization,
indicating its speciﬁcity for NF-kB (Figure 2a). Experiments
with a shorter time interval did not add information on the
kinetics of this activation, conﬁrming a single peak at 6h
after treatment (data not shown). Moreover, supershift
experiments using speciﬁc antibodies to p50 and to p65
NF-kB subunits indicated the involvement of both p65 and
p50 subunits in the activated complex (Supplementary
Figure S1). These data suggested that AZT induced a
triphasic response in NF-kB activation.
However, non-radioactive EMSA could not be considered a
quantitative method for detecting NF-kB activation. Thus, to
conﬁrm and quantitatively characterize the observed
phenomenon, NF-kB activation in U937 cells, either treated
with vehicle or with 128mM AZT, was measured in cell nuclear
lysates by assaying the DNA-binding activity of phosphory-
lated p65 at 0.5, 1, 3, 6, 18 and 24h. The results, shown in
Figure 2b, are expressed as the ratio of the DNA-binding
activityof phosphorylated p65 in AZT-treated cells versusthat
evaluated in the corresponding control samples (AZT/CTR).
After 30 minutes of treatment with AZT, an early slight
inhibition of the AZT/CTR ratio was observed. Then, a
progressive increase in the AZT/CTR DNA-binding activity
occurredwitharaisedpeakafter6hoftreatment(P¼0.033in
comparison with time 0). The AZT/CTR DNA-binding activity
of p65 decreased remarkably in the successive 18 and
24h time points. These results clearly conﬁrmed and
improved those observed by EMSA. To further investigate
the ability of AZT to directly modulate p65, the expression of
Figure 2 Effect of AZT on NF-kB activation. (a) U937 cells were either treated
with vehicle or treated with 128mM AZT and after 0.5, 6 and 24h, NF-kB complex
activation was assayed by non-radioactive EMSA. Speciﬁcity of signal was
assessed in one sample (AZT 6h) by addition of a 200x times excess of unlabeled
kB-speciﬁc DNA (unlabeled 200x) during the binding reaction. A representative
experiment out of the three performed with similar results is shown. (b) U937 cells
wereeithertreatedwithvehicleortreatedwith128mMAZTandafter0.5,1,3,6,18,
24h, NF-kB activation was quantitatively measured by assaying the DNA-binding
activityofthephosphorylatedp65proteinbyELISA.Theresultsarethemeansfrom
three independent experiments performed on U937 cells and have been expressed
as ratio of p65-binding activity in AZT-treated cell versus control samples at each
time of the kinetics (AZT/CTR); asterisk indicates a signiﬁcant difference versus
time 0 (*Po0.05). (c) Expression of phosphorylated p65 was examined by ﬂow
cytometry in ﬁxed U937 cells stained with a FITC-conjugated anti-rabbit IgG and
rabbit anti-phospho-p65 plus goat FITC-conjugated anti-rabbit IgG 30min (upper
panels) and 6h (lower panels) after treatment with 128mM AZT (ﬁlled peak). The
results are one representative of three experiments performed
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Cell Death and Diseasephosphorylated p65 was assayed by MAb staining and ﬂow
cytometry analysis in ﬁxed U937 cells at 0.5 and 6h after
treatment with 128mM AZT. After 0.5h, cells treated with
128mM AZT showed a lower phospho-p65 expression with
respect to the control sample (Figure 2d, upper right panel,
ﬁlled peak versus open peak, respectively). In contrast, after
6h of treatment with AZT, a well-deﬁned shift of the peak
toward the right side conﬁrmed the increased p65 expression
in drug-treated cells in comparison with control cells
(Figure 2d, lower right panel, ﬁlled peak versus open peak,
respectively). Fluorescein isothiocyanate (FITC)-only stained
U937 cells did not exhibit any shift in the ﬂuorescence peak
(Figure 2d, left panels). Taken together, these data show that
AZT actually induced a remarkable peak of NF-kB activation
at 6h after treatment, as demonstrated using three different
techniques.
AZT-induced apoptosis is enhanced in U937 cells in
which NF-jB activation is impaired by stable trans-
fection with a dominant negative IjBa and is dependent
on protein neo-synthesis. Having demonstrated that AZT
induced a consistent, even if transient, increase in NF-kB
DNA-binding activity, we wanted to further investigate the
role of this phenomenon in AZT-induced apoptosis. For this
purpose, experiments were carried out in U937 cells in which
NF-kB activation was impaired by stable transfection with a
dominant negative murine IkBa (U937-mIkB), previously
generated for other purpose in our laboratory.
31 Suscepti-
bility to apoptosis was measured in both U937-mIkB and
U937 cells transfected with the empty vector (U937-pcDNA)
after 48h of treatment with 0, 8, 32 and 128mM AZT. The
results in Figure 3a show that the percentage of hypodiploid
nuclei was consistently higher in U937-mIkB cells (25, 46
and 69%) than in U937-pcDNA cells (16, 24 and 40%) at 8,
32 and 128mM AZT, respectively. The differences between
U937-mIKB values and those of control U937-pcDNA were
statistically signiﬁcant at all the drug concentrations assayed
(8mM AZT, P¼0.042; 32mM AZT, P¼0.036; 128mM AZT,
P¼0.020). Moreover, the percentage of hypodiploid nuclei
in U937-mIkB cells treated with 32 and 128mM AZT was
signiﬁcantly higher with respect to the control (Pr0.001),
whereas in U937-pcDNA cells, only the treatment with
128mM AZT induced a signiﬁcant increase in percentage of
hypodiploid nuclei in comparison with vehicle-treated cells
(P¼0.004). Thus, inhibition of NF-kB activation rendered
target cells remarkably more susceptible to AZT-induced cell
death. To assess how important was the neo-synthesis of
pro-apoptotic or anti-apoptotic proteins in the observed
phenomenon, U937-pcDNA and U937-mIkB cells were
incubated in the presence or in the absence of 0.1mg/ml
cycloheximide (CHX) before the addition of 8, 32 and
128mM AZT. The susceptibility to apoptosis was measured
after 48h (Figure 3b). U937-pcDNA cells treated with CHX
underwent apoptosis at signiﬁcantly lower level than the
control counterpart at the concentration of 128mM AZT
(P¼0.027). Also, U937-mIkB cells treated with CHX were
susceptible to apoptosis at signiﬁcant lower level in the
presence of 32 and 128mM AZT (32mM, P¼0.036; 128mM
AZT, P¼0.009). These results indicated that neo-synthe-
sized proteins fundamentally contributed in determining
apoptosis levels in AZT-treated U937 cells independently
on NF-kB activation.
AZT upregulates the expression of anti-apoptotic
proteins in U937-pcDNA but not in U937-mIjB
cells. Results of previous experiments indicated that the
downregulation of NF-kB signaling rendered AZT-treated
cells more prone to undergo apoptosis, with respect to the
NF-kB competent control cells. We then hypothesized that
the reason for this might lie in the fact that impairment of
NF-kB activation in AZT-treated U937-mIkB inhibited the
upregulation of some NF-kB-dependent anti-apoptotic
proteins by AZT, as predicted by SuperArray analysis. To
test this hypothesis, we investigated the dose- and time-
dependent expression of some NF-kB-dependent anti-
apoptotic proteins in U937-pcDNA and in U937-mIkB
transfectants. Proteins of the IAP family, such as c-IAP2,
X-IAP and survivin, were assayed by western blot analysis
before (t0) and after 3, 6 and 18h of treatment with 8, 32 and
128mM AZT. Figure 3c and d report immunoblot visualization
and densitometry analysis, respectively, from one represen-
tative experiment out of the three performed with similar
results. Results show that c-IAP2 expression increased in
AZT-treated U937-pcDNA cells with respect to the control at
3h after treatment with the higher concentration, as well as
with all the concentrations assayed at 18h. Conversely,
practically identical levels of c-IAP2 expression were
detected, independently of the AZT concentration and the
time of observation, in U937-mIkB cells. In U937-pcDNA
cells, the survivin expression increased at 18h after addition
of 8, 32 and 128mM AZT with respect to the control, whereas
in U937-mIkB cells, survivin expression was not modulated
at all by AZT. Similarly, also the expression of X-IAP in
AZT-treated U937-pcDNA cells showed a peak after 18h in
culture. Essentially, no evident upregulation of X-IAP was
observed in U937-mIkB cells after AZT treatment at all times
assayed. These data conﬁrmed at protein level the increased
transcriptional expression of some anti-apoptotic genes by
AZT and demonstrated that NF-kB activation was, at least in
part, responsible for this upregulation.
Treatment with a pharmacological inhibitor of NF-jB
enhances the susceptibility to AZT-induced cell death in
U937 cells. The above reported data indicated that AZT
directly affect NF-kB activation and that this activation could,
in turn, control the apoptotic response to AZT. We then
investigated whether the combination of a pharmacological
inhibitor of NF-kB with AZT could affect drug-induced cell
death. To this purpose, U937 cells were treated with AZT
in the absence or in the presence of the chemical inhibitor
of NF-kB, Bay 11–7085, at a concentration of 1mM. This
concentration was considered to be suitable for a combi-
nation treatment with AZT on the basis of preliminary dose-
dependent experiments which showed that Bay 11–7085 at
1mM did not induce signiﬁcant apoptosis by itself on U937
cells (data not shown). Figure 4 shows that the co-treatment
with Bay 11–7085 signiﬁcantly increased the susceptibility of
U937 cells to apoptosis already at 24h after addition of 8, 32
and 128mM AZT, in comparison with cells which were not
incubated with the NF-kB inhibitor, in a dose-dependent
NF-jB and AZT-induced apoptosis
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Cell Death and Diseasemanner. Moreover, combination treatment with Bay 11–7085
and 8 or 32mM AZT signiﬁcantly enhanced the suscepti-
bility of U937 cells to apoptosis in comparison with the
AZT-treated control cells (8mM AZT, P¼0.032; 32mM AZT,
P¼0.039). Combination treatment with Bay 11–7085 and
128mM AZT induced an increased level of apoptosis with
respect to AZT alone, but the difference was not statis-
tically signiﬁcant. Thus, the combination of low, non-toxic
concentrations of both AZT and a pharmacological NF-kB
inhibitor sensitized U937 cells to apoptotic cell death.
Figure3 EnhancementofAZT-inducedapoptosisinU937cellsstablytransfectedwithadominantnegativeIkBaanditsdependencyonproteinsynthesisandassociation
with failure of regulation of anti-apoptotic proteins. (a) U937-mIKB cells knock out for NF-kB (ﬁlled column) and their control counterpart U937-pcDNA (empty column) were
treatedwith0,8,32and128mMAZTfor48h.Apoptosiswasevaluatedbyﬂowcytometryanalysisofhypodiploidnucleiandexpressedasmeanvalues±S.E.obtainedfrom
three independent experiments; asterisks indicate signiﬁcant difference between the two cell lines (*Po0.05 or **Po0.010). (b) U937-pcDNA and U937-mIkB cells were
incubatedinthepresence(ﬁlledcolumn)or intheabsence(emptycolumn) ofan inhibitorofprotein synthesis,theCHX, at0.1mg/ml,beforeadditionof 8,32 and128mMAZT
and susceptibility to apoptosis was measured after 48h. Data are the means of hypodiploid nuclei ± S.E. from three experiments carried on in the same culture conditions.
(c) U937-mIkB and U937-pcDNA cells were treated with 0, 8, 32 and 128mM AZT. Expressionof c-IAP, survivin and X-IAPwas assessed by western blot analysisbefore (t0)
and after 3, 6 and 18h of treatment with AZT. One experiment representative of the three independent experiments performed is shown. b-actin expression, run on the same
gel of X-IAP, indicates that an equal amount of protein was loaded for each sample. (d) Western blot analysis was quantiﬁed by densitometry analysis and values are
expressed as OD-Bkg /mm
2 with respect to vehicle
NF-jB and AZT-induced apoptosis
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In this study, we addressed the issue of mechanisms
underlying potential pathological effects of AZT-based
therapy and the possible roles of apoptosis modulation and
NF-kB activation in these adverse effects. Having observed,
using U937 cells as an experimental model, that AZT induced
apoptotic cell death only at relatively high concentration of
128mM, after 48h in culture and in a minority of the cell
population, the unexpected, novel ﬁnding of this ﬁrst part of
our study was that in the same experimental conditions, we
found the upregulation of both pro-apoptotic and anti-
apoptotic gene transcripts. Thus, variability in the balance of
upregulated pro-apoptotic and anti-apoptotic gene products
could account for the variable susceptibility or resistance to
AZT-induced apoptosis observed at different drug concentra-
tions as well as, at the same drug concentration, at individual
cell level. In this context, it is worthy to also note that neo-
synthesis of proteins was necessary for induction of sig-
niﬁcant levels of apoptosis by AZT and that the kinetics of the
effect was characterized by a delayed induction of apoptosis,
with maximal values at 48h. Moreover, we must take into
consideration that SuperArray analysis revealed that tran-
scripts for the DNA-repair genes, GADD45A, MDM2 and
ATM, were upregulated by AZT (Supplementary Table S1).
Upregulation of GADD45A and MDM2 transcripts byAZT was
also conﬁrmed at protein level (Supplementary Figure S2).
Thus, the general picture which emerges from these results
suggests that the appearance of apoptotic cell death in part of
the cells following exposure to high concentration of AZT
could be the ﬁnal consequence of the cell response to DNA
damage. In addition, lack of functional p53 protein in U937
cells excludes the involvement of this functional protein in the
observed phenomena.
Inthis context,wewereparticularlyattractedbythefactthat
treatment of U937 cells with AZT was associated with the
transcriptional activation of several genes related to the
NF-kB survival pathway. Therefore, we investigated whether
this observation was associated with a direct capacity of
AZT to modulate the NF-kB activation process. In fact, we
demonstrated that AZT induced an early and transitory
NF-kB inhibition, as demonstrated by different techniques.
Surprisingly, however, a longer observation revealed that
after 6h of treatment, a remarkable activation of NF-kB could
be consistently detected in all experiments. These data are
apparently in contrast with studies sustaining that the AZT-
induced apoptosis in B-cell malignancy occurred through
inhibition of NF-kB activation.
29,30 However, we noted that in
one of these studies, actually, after an initial inhibition, the
NF-kB-binding activity of AZT-treated samples was increased
in comparison with that of control samples.
30
Interestingly, our study ascertained that the NF-kB system
is actually able to affect the susceptibility to AZT-induced
apoptosis. Experiments carried out in dominant negative
murine IkBa U937 cells revealed that the impairment of
the machinery of NF-kB activation remarkably increased
the susceptibility of U937 cells to AZT-induced apoptosis.
Coherently, U937-mIkB cells were unable to upregulate
anti-apoptotic genes upon treatment with AZT. Therefore,
ourresultsfundamentallyagreewithpreviousreportsfromour
and other laboratories showing that AZT has a negligible pro-
apoptotic effect, but also indicate for the ﬁrst time a possible
explanation for this observation. In fact, the demonstration
that AZT by itself induces a consistent NF-kB activation,
following an initial inhibition, could be the reason why an anti-
apoptotic response, rather then a pro-apoptotic response,
tends to prevail in some conditions following AZT treatment.
However,atthesametime,resultsofourstudysupposethata
biological or pharmacological condition associated with
inhibition of NF-kB activation could considerably increase
the cytotoxic potential of the drug. This should be taken into
particular consideration when treating pregnant women
for additional risk of toxic effects to fetus or newborn. The
other side of the medal is that our ﬁndings suggest that
a combination treatment with NF-kB inhibitors should be
considered in case the therapeutic goal would be represented
by a decreased risk of genotoxic/mutagenic response to AZT
treatment. The task of such a combination therapy with AZT
and NF-kB inhibitors could be to route DNA-damaging events
toward induction of apoptosis, tipping the balance toward
death rather than toward accumulation of gene mutations to
decrease the mutagenic/transforming potential of AZT. This
should be taken into consideration when treating HIVþ
patients at high risk to develop cancer or in whom cancer has
been already diagnosed, with AZT. In particular, such a
combination therapy could be of particular effectiveness in
pathological situations in which cancer is associated with
retroviral infections, such as HIV-associated neoplasias or
adult T-cell leukemia.
Besides, our study could contribute to deﬁne a possible,
anti-tumoralpotentialofAZT,orothernucleosidecompounds,
in combination with NF-kB inhibitors, also for the control of
neoplastic diseases other than those associated with retro-
viral infections. Moreover, our study sustains the general idea
thateffectsofchemotherapeuticdrugsdonotexclusivelyliein
their ability to directly induce DNA damage and alteration of
Figure 4 Increase in susceptibility to AZT-induced cell death by pharmaco-
logical inhibition of NF-kB. U937 cells were treated for 24h with vehicle or 8,
32, 128mM AZT in the absence (open column) or in the presence (ﬁlled column)
of a chemical inhibitor of NF-kB, Bay 11–7085, at a concentration of 1mM. The
means±S.E. of hypodiploid nuclei percentages from three independent
experiments are shown; asterisks indicate signiﬁcant differences versus control
samples at each concentration of AZT (*Po0.05)
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Cell Death and Diseasethe cell cycle control, but that repair mechanisms of DNA or
cell cycle damage in response to chemotherapy could, ﬁnally,
indirectly lead to apoptosis.
Taken together, our results disclose new mechanisms
underlying the effect of AZT on survival/death of target cells.
Given the basic knowledge regarding the biology of both viral
infections and tumors, modulation of NF-kB activation could
be a critical step in determining the adverse or desired effects
of AZT in patients.
Materials and Methods
Cell cultures. Human monocytic U937 cells, originally obtained from
Zooproﬁlactic Institute (Brescia, Italy), were grown in suspension culture at a
density of 4 10
5 cells/ml in RPMI 1640 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS; Invitrogen), 2mM glutamine
(Hyclone, Cramlington, England, UK), 50U/ml penicillin and 50U/ml streptomycin
(Hyclone) at 371C in a 5% CO2-humiﬁed atmosphere, in the presence or not of the
dideoxynucleoside analog 30-azido-30-deoxythymidine (AZT, Wellcome Research
labs, Beckenham, Kent, UK), for different times and at different concentrations
(range: 8–128mM). In some experiments, U937 cells were pre-treated with a
chemical IkBa inhibitor, Bay 11–7085 (SuperArray Bioscience Corporation,
Frederick, MD, USA) 1h before adding AZT, and apoptosis was evaluated at
24h. U937 stable transfectants carrying a dominant negative murine IkBa
(U937-mIkB) or a control vector pcDNA3.1 (U937-pcDNA)
31 were cultured at a
density of 4 10
5 cells/ml in complete RPMI 1640 supplemented with 10% FBS
and 400mg/ml of G418 (Invitrogen) and treated with or without AZT for various
times. In some experiments, both U937-mIkB and U937-pcDNA were pre-treated
with CHX 0.1mg/ml (Sigma, St. Louis, MO, USA) for 1h, and apoptosis was
evaluated48hinpresenceorinabsenceofAZT.Followingincubationinthevarious
culture conditions above described, cells were harvested and washed three times
with cold phosphate-buffered saline (PBS) for 5min, at 1000 g, þ41C, and then
used for RNA and protein extractions or for intracellular staining to evaluate protein
expression and apoptosis.
Apoptosis assays. Apoptosis was evaluated by ﬂow cytometry analysis of
isolated nuclei following detergent treatment and PI staining, using a method that
distinguishes nuclei from apoptotic, necrotic or viable cells, as previously
described.
32 Brieﬂy, harvested cells were treated with a solution of PI at 25mg/ml
(PI, Sigma) plus 0.05% sodium citrate (Sigma) and with detergent at a high
concentration (20% Triton X-100, Sigma) for 30min. Isolated nuclei were then
analyzed using a FACScan ﬂow cytometry (BD Biosciences, Mountain View, CA,
USA). Detectors and ampliﬁer gains for forward and orthogonal scatter were
adequately selected to simultaneously detect nuclei from viable, apoptotic and
necrotic cells. Events were gated on forward versus orthogonal scatter in such a
way that degraded DNA from cell debris or from doublets was excluded and nuclei
from viable, apoptotic and necrotic cells were assayed. Data acquisition and
analysiswereperformedusingCellQuestsoftwareonaminimumof5000eventsfor
each sample (BD Biosciences, San Jose, CA, USA). In some experiments, the
Annexin V-FITC Apoptosis Detection Kit (BD-Bioscience Pharmingen, San Diego,
CA, USA) was used, according to the manufacturer’s instructions, to detect
apoptosis.Brieﬂy,5 10
5 cells wereincubated for 15min with annexin-V-FITCand
then washed in annexin buffer. Cells were analyzed immediately after staining by
ﬂow cytometry analysis using a FACScan ﬂow cytometer and Cell Quest software.
Immune staining and ﬂow cytometry analysis of phospho NF-jB
p65. For analysis of intranuclear NF-kB p65 proteins, 2 10
6 cells were ﬁxed in
0.5ml of 1% paraformaldehyde in PBS for 10min at 371C, and successively after
being washed twice in PBS, in 90% methanol for 10min at 41C. Samples were ﬁrst
incubated with a rabbit monoclonal antibody against phospho NF-kB p65 Ser (536)
(Cell Signaling Technology, Danvers, MA, USA) for 30min at 41C and then
stained with goat FITC-conjugated anti-rabbit IgG (Harlan Sera-Lab Ltd., Belton
Loughborough, UK). Cells were analyzed immediately after staining by ﬂow
cytometry using a FACScan ﬂow cytometry and CellQuest software.
NF-jB-binding assays. For detecting NF-kB activation by non-radioactive
EMSA, nuclear extracts from cells subjected to different experimental conditions
werepreparedas follows. Aliquotsof 10
7 cells weresuspendedin 400ml of buffer A
(10mM HEPES, pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM dithiothreitol, 0.2mM
phenylmethylsulphonyl ﬂuoride, all from Sigma), incubated on ice for 15min and
homogenizedby15 passagesthrougha 25-gaugeneedle.Thenucleiwerepelleted
by centrifugation at 10000 g for 40s at 41C, washed in 150ml of buffer A and
re-suspended in buffer B (20mM HEPES, pH 7.9, 25% glycerol, 0.42M NaCl,
1.5mM MgCl2, 0.2mM EDTA, 0.5mM dithiothreitol, 0.5mM phenylmethylsulphonyl
ﬂuoride)supplementedwith1  proteaseinhibitorcocktail(RocheAppliedScience,
Indianapolis, IN, USA). After 30min of incubation on ice, the nuclear extracts were
collected by centrifugation at 10000 g for 2min. The extracts were rapidly frozen
on dry ice and stored at  801C until processed for EMSA. Before freezing, the
protein concentration was estimated using an assay kit (Bio-Rad Laboratoires,
Richmond, CA, USA). After thawing, groups of nuclear extracts were collectively
subjected to EMSA using reagents provided in the ‘LightShift chemiluminescent
EMSA Kit’ (Pierce, Rockford, IL, USA). Aliquots of B10mg of the extracts
were mixed with 1–10pmoles of biotin-labeled kB DNA probe (AG
TTGAGGGGACTTTCCCAGGC) and poly(dI-dC) in binding buffer (10mM Tris,
100mM NaCl, 1mM EDTA, 1mM dithiothreitol, 5% glycerol, pH 7.5) in a ﬁnal
volume of 15ml. Binding reactions were incubated for 20min at room temperature.
The dye solution was then added and samples were directly loaded onto a 5%
polyacrylamide gel in 0.5  TBE buffer for running. The gels were then transferred
to ‘Zeta-probe GTGenomic’ blottingmembranes(Bio-Rad)andvisualizedusingthe
‘chemiluminescent nucleic acid detection module’ provided in the EMSA kit.
Speciﬁcity of the protein–DNA complex was veriﬁed by incubating the nuclear
extracts for 30min on ice with 2mg of polyclonal antibodiesto p65 (Rel A) or to p50,
before the binding reaction and, in competition experiments, with a 200x excess of
unlabeled kB-speciﬁc DNA.
For quantization of NF-kB p65 binding by an enzyme-linked immunosorbent
assay(ELISA),nuclearextractsfromcellsculturedfordifferenttimeswithor without
AZT were obtained as described above. Protein concentration of each sample was
determined by BCA protein Assay Kit (Pierce). The DNA-binding activity of NF-kB
p65 was measured using a commercial ELISA according to the manufacturer’s
protocol (Trans-AM NF-kB p65 Transcription Factor Assay Kit; Active Motif North
America, Carlsbad, CA, USA). The absorbance was determined at 450nm
with wavelength correction 650nm using a Labsystem Multiskan Bichromatic
spectrophotometer (Helsinki, Finland).
Western blot analysis. A total number of 3 10
6 cells were solubilized at
41C in lysis buffer (50mM Tris-HCL pH 7.4, 1mM EDTA, 1mM EGTA pH 7.4, 1%
Triton-X,150mMNaCl,0.25%sodiumdeoxycholate,1%NP-40and,freshlyadded,
1mM PMSF, 5mM DTT, 1mg/ml leupeptin, 1mg/ml pepstatin, 2mg/ml aprotinin,
1mM Na 3VO4,2 0 m MN a 3F, all from Sigma) and centrifuged at 10000 g for
20min. An certain amount of protein obtained from 5 10
5 cells was loaded onto a
10% SDS-polyacrylamide gel, subjected to electrophoresis and transferred to
nitrocellulose membrane (Bio-Rad laboratories, Hercules, CA, USA), which was
subsequently stained with 0.2% Ponceau red to ensure equal protein loading and
transfer. After blocking the membrane in 10% non-fat dried milk and 3% BSA in
TTBS (20mM Tris-HCl pH 8.0, 0.9% NaCl, 0.03% Tween 20, all from Sigma), the
blots were incubated overnight at 41C with diluted primary antibody and,
subsequently, washed and then incubated with anti-mouse (Bio-Rad laboratories)
or anti-rabbit or anti-goat IgG chain-speciﬁc conjugated to peroxidase (Calbiochem,
Merck Biosciences, Darmstadt, Germany). Binding of antibodies was detected by
chemiluminescence staining using the ECL detection kit (Amersham Biosciences,
Little Chalfont, UK). The following antibodies where used: rabbit polyclonal
antibodiesagainst humansurvivin(1:1000, R&DSystem,Minneapolis,MN, USA),
humanX-IAP(1:1000, R&DSystems),humanc-IAP2 (H-85;1:1 000,SantaCruz
Biotechnology, Santa Cruz, CA, USA), human MDM2 (1:500, Chemicon
International, Temecula, CA, USA) and mouse monoclonal antibodies against
GADD-45A (1:200, Abnova Corporation, Taipei, Taiwan) and human b-actin
(1:8000, Novus Biologicals, Inc., Littleton, CO, USA). Comparative analysis of the
bands was performed by quantitative densitometry using the Tina software (version
2.10, Raytest, Straubenhardt, Germany).
SuperArray. RNA isolation was performed using RNAzol (Invitrogen, Grand
Island,NY,USA),accordingtothemanufacturer’sinstructions.Anamountof3.5mg
of total RNA was used in a reverse transcription (RT) reaction with biotin-16-dUTP
(Roche Diagnostics GmbH). RT reaction was performed using Ampolabelling LPR
kit (SABioscience Corporation, Frederick, MD, USA). The labeled cDNA was
incubated with GEArray-Q Series human apoptosis and cell cycle membranes
(SuperArray, SABioscience) at 601C overnight. The membrane used in the present
NF-jB and AZT-induced apoptosis
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pathways, in addition to positive control genes (glyceraldehydes-3-phosphate
dehydrogenase, GAPDH, cyclophillin A and b actin). After being washed, the
membrane was incubated with streptavidin-alkaline phosphatase and was ﬁnally
exposed to CDP-Star chemiluminescent substrate (SuperArray). Signal detection
was performed using a high Performance chemiluminescence ﬁlm (Amersham
Biosciences). Analysis of results was performed by GEArray Expression Analysis
Suite software (http://geasuite.superarray.com). According to this analysis,
transcriptional levels of genes showing fold change values of 41.50 or o0.66
were considered signiﬁcantly modiﬁed. SuperArray analysis results are provided as
Supplementary material (Supplementary Table S1).
Statistical analysis. Data analysis was performed using the SPSS statistical
software system (Chicago, IL, USA). Statistical probabilities were expressed as
Po0.05 (*) or Po0.010 (**). Comparison of means of apoptosis or p65 activation
levels in response to AZT treatment was carried out using Bonferroni’s post hoc
multiplecomparisonANOVAtest.Comparisonofmeansofvaluesbetweendifferent
cell lines or after treatment with CHX or NF-kB inhibitor was carried out using the
independent samples Student’s t-test.
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